Zydus Lifesciences Ltd. has described compounds reported to be useful for the treatment of dengue virus infections.

Flagship Pioneering Innovations VI LLC has synthesized ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors.

Scientists at Apichope Bio Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker acting as IRAK-4 degradation inducers.

Nimbus Wadjet Inc. has disclosed compounds reported to be useful for the treatment of cancer.

Scientists at Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have described GTPase KRAS and/or its mutant inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a target protein binding moiety through a linker reported to be useful for the treatment of cancer, dermatological, neurological, respiratory and cardiovascular disorders, autoimmune diseases, infections and transplant rejection, among others.

Researchers at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified aromatic amide derivatives acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Scientists at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed pyridazinopyridone derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors. As such, they are reported to be useful for the treatment of cancer, gingival fibromatosis, cardiofaciocutaneous and Noonan syndromes.

Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.